ATE471313T1 - 3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel - Google Patents

3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel

Info

Publication number
ATE471313T1
ATE471313T1 AT07703028T AT07703028T ATE471313T1 AT E471313 T1 ATE471313 T1 AT E471313T1 AT 07703028 T AT07703028 T AT 07703028T AT 07703028 T AT07703028 T AT 07703028T AT E471313 T1 ATE471313 T1 AT E471313T1
Authority
AT
Austria
Prior art keywords
supressive
isoxazoles
oxadiazoles
heteroaryl
aryl
Prior art date
Application number
AT07703028T
Other languages
English (en)
Inventor
Rainer Albert
Frederic Zecri
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE471313T1 publication Critical patent/ATE471313T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
AT07703028T 2006-01-27 2007-01-25 3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel ATE471313T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0601744.6A GB0601744D0 (en) 2006-01-27 2006-01-27 Organic compounds
PCT/EP2007/000638 WO2007085451A2 (en) 2006-01-27 2007-01-25 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents

Publications (1)

Publication Number Publication Date
ATE471313T1 true ATE471313T1 (de) 2010-07-15

Family

ID=36061049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07703028T ATE471313T1 (de) 2006-01-27 2007-01-25 3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel

Country Status (16)

Country Link
US (1) US7799812B2 (de)
EP (2) EP2233473A1 (de)
JP (1) JP2009524611A (de)
KR (1) KR20080091161A (de)
CN (1) CN101374821A (de)
AT (1) ATE471313T1 (de)
AU (1) AU2007209533A1 (de)
BR (1) BRPI0707285A2 (de)
CA (1) CA2637081A1 (de)
DE (1) DE602007007186D1 (de)
ES (1) ES2347015T3 (de)
GB (1) GB0601744D0 (de)
PL (1) PL1981858T3 (de)
PT (1) PT1981858E (de)
RU (1) RU2008134534A (de)
WO (1) WO2007085451A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010949A2 (en) 2002-07-30 2004-02-05 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
CA2596990A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
SI1863787T1 (sl) 2005-03-23 2011-10-28 Actelion Pharmaceuticals Ltd Hidrogenirani benzo(c)tiofenski derivati kot imunomodulatorji
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
ATE447568T1 (de) 2006-01-24 2009-11-15 Actelion Pharmaceuticals Ltd Neue pyrinderivate
RU2008134702A (ru) 2006-01-27 2010-03-10 Юниверсити Оф Вирждиния Пэтент Фаундейшн (Us) Способ лечения невропатической боли
EP1987013A1 (de) 2006-02-09 2008-11-05 University Of Virginia Patent Foundation Bicyclische sphingosin-1-phosphat-analoge
ES2400533T3 (es) 2006-09-07 2013-04-10 Actelion Pharmaceuticals Ltd. Derivados de piridin 4-ilo como agentes inmunomoduladores
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
SI2069335T1 (sl) 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
RU2442780C2 (ru) 2006-09-21 2012-02-20 Актелион Фармасьютиклз Лтд Фенильные производные и их применение в качестве иммуномодуляторов
EP2099741A2 (de) 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindan-analoga mit sphingosin-1-phosphatrezeptoragonistenaktivität
NZ576893A (en) 2006-11-21 2012-01-12 Univ Virginia Patent Found Tetralin analogs having sphingosine 1-phosphate agonist activity
CA2669124A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
MX2009006304A (es) 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
KR20090130062A (ko) * 2007-04-19 2009-12-17 글락소 그룹 리미티드 스핑고신 １―포스페이트 (ｓ１ｐ) 효능제로서 사용하기 위한 옥사디아졸 치환된 인다졸 유도체
RU2492168C2 (ru) 2007-08-17 2013-09-10 Актелион Фармасьютиклз Лтд Производные пиридина в качестве модуляторов s1p1/edg1 рецептора
WO2009053481A1 (en) * 2007-10-25 2009-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for modulating nk and t cell trafficking
KR20100092473A (ko) * 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
BRPI0820868A2 (pt) 2007-12-10 2019-09-24 Actelion Pharmaceuticals Ltd composto de tiofeno fórmula(i), composição farmacêutica contendo o mesmo e uso deste para a prevenção ou tratamento de doenças ou disturbíos associados a um sistema imune ativado
US9045442B2 (en) 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
EP2262799B1 (de) * 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridinverbindungen
EP2262800A1 (de) * 2008-03-06 2010-12-22 Actelion Pharmaceuticals Ltd. Neuartige pyrimidin-pyridin-derivate
MX2010009645A (es) 2008-03-07 2010-09-28 Actelion Pharmaceuticals Ltd Derivados novedosos de aminometil benceno.
WO2010011316A1 (en) 2008-07-23 2010-01-28 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
MX2011002199A (es) 2008-08-27 2011-05-10 Arena Pharm Inc Derivados de acidos triciclicos substituidos como agonistas del receptor s1p1 utiles en el tratamiento de trastornos autoinmunes e inflamatorios.
EP2210890A1 (de) * 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazol Derivate als S1P1 Rezeptor Agonisten
JP2012515788A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
US8354398B2 (en) 2009-01-23 2013-01-15 Bristol-Myers Squibb Company Substituted isoxazole compounds
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
KR101409131B1 (ko) 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
ES2558087T3 (es) 2010-03-03 2016-02-01 Arena Pharmaceuticals, Inc. Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos
US8273776B2 (en) * 2010-04-16 2012-09-25 Allergan, Inc Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators
EP2560969B1 (de) * 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl und 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelsäureamide als sphingosin-1-phosphate 1 rezeptor agonisten
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
EP2595969B1 (de) 2010-07-20 2015-04-22 Bristol-Myers Squibb Company Substituierte 3-Phenyl-1,2,4-Oxadiazolverbindungen
US9187437B2 (en) 2010-09-24 2015-11-17 Bristol-Myers Squibb Company Substituted oxadiazole compounds
ES2544086T3 (es) 2011-01-19 2015-08-27 Actelion Pharmaceuticals Ltd. Derivados de 2-metoxi-piridin-4-ilo
EP2570404A1 (de) * 2011-09-16 2013-03-20 Syngenta Participations AG. Verbindungen zur Regulierung des Pflanzenwachstums
CN104428296B (zh) 2012-07-02 2017-11-14 孟山都技术公司 制备3，5‑二取代‑1，2，4‑噁二唑的方法
US10662164B2 (en) 2014-09-25 2020-05-26 University Of Notre Dame Du Lac Non-beta lactam antibiotics
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
BR112017024785B1 (pt) 2015-05-20 2022-05-17 Idorsia Pharmaceuticals Ltd Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3- il]-2-etil-6-metilfenoxi}-propano-1,2-diol, composição farmacêutica, e, uso
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
WO2018049404A1 (en) 2016-09-12 2018-03-15 University Of Notre Dame Du Lac Compounds for the treatment of clostridium difficile infection
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
CN111518091B (zh) * 2020-04-22 2023-02-03 安徽医科大学 一种1，2，4-噁二唑并吡啶类化合物ahmu07及其作为抗菌药物的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015213A1 (fr) 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive
DE19904389A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
BR0110211A (pt) 2000-04-21 2003-06-03 Shionogi & Co Derivados de oxadiazol tendo efeitos anticâncer
WO2001083464A1 (fr) * 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire
NZ525656A (en) 2000-11-07 2004-12-24 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
WO2003000249A1 (fr) * 2001-06-26 2003-01-03 Takeda Chemical Industries, Ltd. Regulateur de la fonction du recepteur relatif aux retinoides
WO2003035610A1 (fr) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Derive de sulfonamide a effet inhibiteur sur les mmp
US20050227994A1 (en) * 2002-03-27 2005-10-13 Shionogi & Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
KR20050084224A (ko) 2002-12-09 2005-08-26 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 야누스 티로신 키나제 3을 선택적으로 저해하는 방법
EP1625123A4 (de) * 2003-05-15 2007-08-29 Merck & Co Inc 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazole als s1p-rezeptoragonisten
MXPA05012460A (es) * 2003-05-19 2006-05-25 Irm Llc Compuestos y composiciones inmunosupresoras.
US7825146B2 (en) * 2003-07-30 2010-11-02 Shionogi & Co., Ltd. Sulfonamide derivative having isoxazole ring
CA2539438A1 (en) * 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
CN1894225A (zh) 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
EP1704145B1 (de) 2004-01-12 2012-06-13 YM BioSciences Australia Pty Ltd Selektive kinaseinhibitoren
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS

Also Published As

Publication number Publication date
KR20080091161A (ko) 2008-10-09
CA2637081A1 (en) 2007-08-02
BRPI0707285A2 (pt) 2011-04-26
WO2007085451A2 (en) 2007-08-02
DE602007007186D1 (de) 2010-07-29
US7799812B2 (en) 2010-09-21
EP1981858B1 (de) 2010-06-16
GB0601744D0 (en) 2006-03-08
WO2007085451A3 (en) 2007-12-21
CN101374821A (zh) 2009-02-25
PL1981858T4 (pl) 2010-12-31
EP1981858A2 (de) 2008-10-22
JP2009524611A (ja) 2009-07-02
ES2347015T3 (es) 2010-10-22
PT1981858E (pt) 2010-09-07
RU2008134534A (ru) 2010-03-10
EP2233473A1 (de) 2010-09-29
PL1981858T3 (pl) 2010-12-31
US20090137636A1 (en) 2009-05-28
AU2007209533A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
ATE471313T1 (de) 3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
NO20092314L (no) Benzamidderivater som EP4 receptoragonister
DE602007009420D1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
NO20084049L (no) Forbindelser med forsterket ampa receptor og anvendelse derav i medisin
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
NO20074895L (no) Isoksazolin derivat og ny fremgangsmate for fremstilling derav
HRP20080552A9 (en) Benzimidazole derivative and use thereof
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
NO20060969L (no) Benzoxazinon avledende sulfonamid forbindelser, deres fremstilling og anvedelse som medikamenter
DE602005014629D1 (de) Pyrazolphenylderivate als ppar-aktivatoren
UY28200A1 (es) Acidos carboxílicos de heteroarilo condensado como agonistas del ppar
NO20091830L (no) Spiro-piperidinderivater som VIa reseptorantagonister
CL2013000027A1 (es) Compuestos derivados de (3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il)metanona, antagonistas del receptor mch1; proceso para prepararlos; composicion farmaceutica; metodo de tratamiento; compuesto intermediario; y su uso para el tratamiento o profilaxis de la obesisdad.
NO20073295L (no) Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
BRPI0606178A2 (pt) derivados de 3-aril-1,2-benzisoxazol e sua utilização como medicamentos contra o cáncer
MXPA03000153A (es) Nuevos derivados de tetrazol.
BR112014009288A2 (pt) formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona
DE602005013118D1 (de) 1h-indol-3-carbonsäurederivate und deren verwendung als ppar-agonisten
CL2008003758A1 (es) Compuestos derivados de 1(2)h-tetrazol-5-il-fenil-oxazolidinonas, procedimiento de preparacion, composicion farmaceutica, util para el tratamiento de infecciones bacterianas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1981858

Country of ref document: EP